The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2023 | Distinguishing between AML and MDS and addressing overlap between these diseases
Manoj Raghavan, MBBS, PhD, FRCPath, MRCP, CCST, University of Birmingham, Birmingham, UK, discusses the challenge of distinguishing between acute myeloid leukemia (AML) and myelodsyplastic syndromes (MDS), and further explains the importance of addressing the overlap between these diseases and determining the best treatment approach for each. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Chief investigator for the national trial in low risk MDS – REPAIR MDS.
Speaker fees and ad boards fees from Pfizer, Jazz Pharma, Astellas, Incyte Pharma.
